

Date : 13/08/2007

IDENTIFICATION

Family name:	Willan	CFI PIN : 51087
Given name and initials:	Andrew R	
Position:	Senior Scientist	
Institution:	The Hospital for Sick Children	
Department:	Child Health Evaluative Sciences	

MAILING ADDRESS (including institution, street and number, municipality, province, and postal code):

Child Health Evaluative Sciences Research Institute Hospital for Sick Children 555 University Avenue			
Toronto			
Ontario			
M5G 1X8			
CANADA			
Office Telephone:	(416) 8132166	Extension:	Fax:
E-mail address:	andy@andywillan.com		
I wish to receive correspondence in: <input checked="" type="radio"/> English <input type="radio"/> French			

ACADEMIC BACKGROUND

Degree type	Year received or expected	Discipline/Field/Speciality	Institution and Country
Doctorate (PhD)	1979	Biostatistics	University of Western Ontario CANADA
Master's	1976	Statistics	Queen's University at Kingston CANADA
Bachelor's	1972	Education	Queen's University at Kingston CANADA
Bachelor's	1970	Economics and Mathematics	York University CANADA

Name: Willan, Andrew

RESERCH CONTRIBUTION IN THE LAST FIVE YEARS

SAMPLE PUBLICATIONS (2006-2011)

1. **Willan AR**, Goeree, R, Pinto EM, McBurney C, Blackhouse G. Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia. *Pharmacoeconomics* 2006; **24**: 93-106.
2. Palencia R, Gafni A, Hannah ME, Ross S, **Willan AR et al.** The costs of planned caesarean versus planned vaginal birth in the Term Breech Trial. *CMAJ* 2006; **174**: 1109-1113.
3. **Willan AR**, Briggs AH. *The Statistical Analysis of Cost-effectiveness Data*. Chichester UK: Wiley 2006.
4. Sofronas M, Ichord RN, Fullerton HJ, Lynch JK, Massicotte MP, **Willan AR**, deVeber G. Pediatric stroke initiatives and preliminary studies: what is known and what is needed? *Pediatric Neurology* 2006; **34**: 439-445.
5. **Willan AR**. Statistical analysis of cost-effectiveness data from randomized clinical trials. *Expert Rev. Pharmacoeconomics Outcomes Res.* 2006; **6**:337-346.
6. Manca A, **Willan AR**. Lost in translation": accounting for between country differences in the analysis of multinational cost effectiveness data. *Pharmacoeconomics* 2006; **24**: 1101-1119.
7. Eckermann S, **Willan AR**. Expected value of information and decision making in HTA. *Health Economics* 2007; **16**: 195-209.
8. Pullenayegum EM, **Willan AR**. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data. *Statistics in Medicine* 2007; **26**: 3274-3299.
9. **Willan AR**. Clinical decision making and the expected value of information. *Clinical Trials* 2007; **4**: 279-285.
10. Hossain A, **Willan AR**. Approximate MLEs of the parameters of location-scale models under type II censoring. *Statistics* 2007; **41**(5): 385-394.
11. Boutis K, **Willan AR**, Babyn P, Narayanan UG, Alman B, Schuh S. A randomized, controlled trial of a removable brace versus casting in children with low-risk ankle fractures. *Pediatrics* 2007; **119**(6): e1256-e1263.
12. Eckermann S, **Willan AR**. Time and EVSI wait for no patient. *Value in Health* 2008; **11**: 522-526.
13. **Willan AR**, Kowgier ME. Cost-effectiveness Analysis of a Multinational RCT with a Binary Measure of Effectiveness and an Interacting Covariate. *Health Economics* 2008; **17**: 777-791.
14. Eckermann S, **Willan AR**. The option value of delay in health technology assessment. *Medical Decision Making*, 2008 **28**: 300-305.
15. Eckermann S, Briggs A, **Willan AR**. Health technology assessment in the cost-disutility plane. *Medical Decision Making* 2008; **28**: 172-181.

16. **Willan AR**, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. *Clinical Trials* 2008; **5**: 289-300.
17. **Willan AR**. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials* 2008; **5**: 587-594.
18. Murphy KE, Hannah ME, **Willan AR** *et al*. Multiple courses of antenatal corticosteroids for preterm birth study (MACS): a randomised controlled trial. *Lancet* 2008; **372**:2143-2151.
19. Eckermann S, **Willan AR**. Globally optimal trial design for local decision making. *Health Economics* 2009; **18**: 203-216.
20. Schuh S, **Willan AR**, Stephens D, Dick PT, Coates A. Can Montelukast Shorten Prednisolone Therapy in Children with Mild to Moderate Acute Asthma? A Randomized Controlled Trial. *Journal of Pediatrics* 2009; **155**: 795-800.
21. Howard AW, Macarthur C, Rothman L, **Willan AR**, Macpherson AK. School playground surfacing and arm fractures in children: a cluster randomized trial comparing sand to wood chip surfaces. *PLoS Med* **6(12)**: e1000195. doi:10.1371/journal.pmed.1000195.
22. Eckermann S, Coory M, **Willan AR**. Indirect comparison: relative risk fallacies and odds solution. *Journal of Clinical Epidemiology* 2009; **62**: 1031-1036. **CA**
23. **Willan AR**, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. *Health Economics* 2010; **19**: 549-561.
24. **Willan AR**. The use of value of information methods in the design and evaluation of clinical trials. In *Economic Evaluation in Child Health*. Ungar WJ. (ed). Oxford University Press 2010.
25. Eckermann S, Karnon J, **Willan AR**. The value of Value of Information: best informing research design and prioritization using current methods. *Pharmacoeconomics* 2010; **28**: 699-709.
26. Hossain A, Beyene J, **Willan AR**, Hu P. Approximate Likelihood ratio test for detecting differential expression in microarray data. *Computational Statistics and Data Analysis* 2009; **53**(10): 3685-3695.
27. Abrahamyan L, Beyene J, Feng JY, Chon Y, **Willan AR**, Schmeling H, Horneff G, Keystone EC, Feldman BM. Response times follow lognormal or gamma distribution in arthritis patients. *Journal of Clinical Epidemiology* 2010; **63**(12): 1363-1369.
28. Abrahamyan L, Li CS, Beyene J, **Willan AR**, Feldman BM. The impact of survival distributions on the power of randomized clinical trials. *Journal of Clinical Epidemiology* 2011; **64**(3): 286-292.
29. Boutis K, **Willan AR**, Babyn P, Goeree R, Howard A. A Randomized Controlled Trial of Cast Versus Splint In Children with Acceptably Angulated Wrist Fractures. *Canadian Medical Association Journal* 2010; **182**(14): 1507-1512.
30. Eckermann S, Coory M, **Willan AR**. Consistently estimating risk difference when translating evidence to jurisdiction of interest. *Pharmacoeconomics* 2011; **29**(2): 87-96.
31. Asztalos E, Murphy K, Hannah ME, **Willan AR**, *et al*. Multiple courses of antenatal corticosteroids for preterm birth study (MACS): 2-year outcomes. *Pediatrics* published online Oct 18, 2010; DOI: 10.1542/peds.2010-0857.

32. **Willan AR**. Sample size determination for cost-effectiveness trials. *Pharmacoeconomics* 2011; **29**(11): 933-949.
33. Harris SB, Kapor J, Lank CN, **Willan AR**, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. *Canadian Family Physician* 2010; **56**: e418- e424.
34. von Keyserlingk C, Boutis K, **Willan AR**, Hopkins R, Goeree R. Cost-Effectiveness Analysis of Cast Versus Splint In Children with Acceptably Angulated Wrist Fractures. *International Journal of Technology assessment in Health Care* 2011; DOI:10.1017/S0266462311000067.
35. Eckermann S, **Willan AR**. Presenting and summarizing cost and effect evidence to best inform inference and societal decision making when comparing multiple strategies. *Pharmacoeconomics* 2011; **29**(7): 563-577.
36. Pullenayegum EM, **Willan AR**. Marginal models for censored longitudinal cost data: appropriate working variance matrices in inverse-probability-weighted GEEs can improve precision. *International Journal of Biostatistics* 2011; **7**(1); www.bepress.com/ijb/vol7/iss1/14.
37. **Willan AR**, Eckermann S. Value of information and pricing new health interventions. *PharmaEconomics* 2011; **29**().
38. **Willan AR**, Eckermann S. Accounting for between-study variation in value of information methodology. *Health Economics* DOI: 10.1002/hec.1781.
39. Ballantyne M, Stevens B, Guttman A, **Willan AR**, Rosenbaum, P. Transition to neonatal follow-up programs – is attendance a problem? *Journal of Perinatal and Neonatal Nursing* (accepted for publication).
40. Freedman SB, Parkin PC, **Willan AR**, Schuh S. Rapid versus standard intravenous rehydration in paediatric gastroenteritis: a pragmatic, blinded, randomised clinical trial. *BMJ* 2011; 343: bmj.d6976.
41. Ungar WJ, Boydell K, Dell S, Feldman BM, Marshall D, **Willan AR**, Wright J. A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma. *Pharmacoeconomics* 2012: (in press).
42. Murphy KE, Hannah ME, **Willan AR et al**. Maternal Side-effects after multiple courses of antenatal corticosteroids (MACS): The three-month follow-up of women in the randomized controlled trial of MACS for preterm birth study. *J Obstet Gynaecol Can* 2011; **33**(9):909–921.